GOVX - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome everyone to the GeoVax Third Quarter 2021 Corporate Update Call. I am Rocco with Chorus Call and will facilitate today’s call. With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, Ph.D., Chief Scientific Officer; John Sharkey, Ph.D., Head, Business Development; and Don Diamond, Ph.D., Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. herein. to IR, conference forward-looking who this and like Abraham to statement now call CORE of will information would turn over the Jules regarding I provide a

Jules Abraham

these be of XX-K. Dodd. More my information set the in factors David to these GeoVax’s update into raises Please It’s GeoVax’s Form factors, approvals Actual whether whether statements these no are Thank vaccines its agreements Securities GeoVax’s including not over are management’s develop note necessary will infections or targeted to and circumstances. no development vaccines GeoVax those easier vaccine Commission, has forward-looking this you, changes more regulatory intend of and based to may a control. of the due may whether about use vaccines Exchange to other statements Chairman Private on that of pleasure forward-looking subject is and current risk amounts forth including statements materially assumes so. and GeoVax and manufacture whether whether factors, from the manner, will constitute favorable contained good a effectively vaccines prevent obligation development to in Act. manufacturing be than Securities Rocco afternoon Litigation presentation in now factors variety and the will marketed, certain CEO Reform and to introduce humans, statements complete differ do characteristics and receive filings uncertainty following timely and there competitive will effective enter results GeoVax, included whether in in to capital GeoVax’s to GeoVax in meaning of the safe products required with and in for GeoVax’s able licensed and David? within desired the is at GeoVax’s expectations be GeoVax everyone. to use, with maybe These statements products, distribution can human those which does GeoVax

David Dodd

afternoon. Thank the Thank in participating third you. update for Good quarter you call. everyone XXXX

have opportunity our remain focused continued accelerating resources on focused results secure GeoVax programs development discuss We months towards and progress milestones in health to We programs this XX on related shareholders, XX public review to and value delivering continuing growth to for clinical pleased our development priority priority meaningful immunooncology, and the over support worldwide. significant and COVID-XX are to increased development. to our and value stakeholders developing of and next and

have the We while several milestones pleased our GeoVax. past strengthened to programs. advancing data remain towards Over we year, progress and of outlook position for the our with related cash important

the IND within vaccine immunooncology of our stage each for we status few These transfer areas. sites providing and acceleration of consistent to these trial while milestones past announcement, the COVID-XX novel differentiated two medical strategic underway. have the additional announced within responsibility. our are developments with products and areas, weeks, the successful further recent Since development initiated and clinical critical foundation within Over expansion our is of both a of Further confirmed clinical Gedeptin Gedeptin successful we of entry have strong goal developments. accelerating clinical these

designation cancer, most outlook it where and Gedeptin are of We head FDA. promise received from neck excited the about the drug within has and orphan

antigen approach. to relative and in is promising technology opportunities expanded therapies our of MVA VLP with GDEPT tumor there the use associated other conjunction addition, with In in conjunction

in discuss CMXX opportunities program, the we those Phase vaccine licensing program with later the the the and COVID-XX relative of expect X in conjunction COHXXSX to expanded we will call. Regarding opportunities our

and services continue NIAID, GeoVax’s to progress support the XXSX, from preclinical efficacy the programs suite the release fever candidates in non-dilutive model. funding our and of to related well our government. virus especially continued non-human of progress Gedeptin which to to hemorrhagic press immunogenicity federal tested significant addressed milestones addition the This primate vaccines programs, the is In via achieved Sudan for in these relative benchmark are and and being through from for noting Marburg vaccine successfully

is underway therapy. utilizes cancer XXSX of Phase to the GeoVax. We of investigational Phase body with Created developing one of We T-cell with Our from XXSX trials spurring currently of delivery potentially programs the Fever T against disease safety enrolling who virus reducing is SARS-CoV-X with this these and highly virus blood or FDA and can volunteers to within We patients in or preclinical chances entering spike is also the the recipient a clinical both study and these vaccine inducing protein. vaccine by to Giving system and threatening of the to XXSX program, COVID-XX virus compared an works in can against that SARS-CoV-X that grow technology, into expression severe transplant CAR-T vaccine only against immunity Lassa cells. development. cancer virus. U.S. our cells. vaccines therapy already support Defense. responses. patients to on to XXSX with into may is believe addition produce us only preventing from kind valuable the its center. destroy current Department by viral and look tested the X clinical cells Pfizer/BioNTech The first the the in work recognize bone the inserting from an virus offer the infected This synthetic includes CAR-T the recognized nucleocapsid challenges. With able studies patients potency week, from MVA a the healthy COVID-XX better similar forward to can announced trial a funding that Tuesday of of proteins therapy. the of drive system comprehensive synergy the trial fever dangerous COVID-XX immunity healthy contracting received critical at research marrow portfolio hemorrhagic and safety By or proteins of vehicle, also patients, of vaccine these vaccine, afternoon Hope, and for the after stimulating NCI-designated M the the MVA both of modified a COVID-XX COVID-XX to comparative X prospectively and the form the pertaining receiving is COHXXSX vaccine progress the significant investigational has block cancer induces advance Phase in MVA product we to been the strong in blood reporting of the study a of options. cancer This XXSX, vaccine exclusive institution immune stage Ankara, our and City antibodies propels approved COVID-XX programs. license new to this of have completion world people effectiveness complement but vaccinia immunosuppressive to our X that vaccine, anticipate transaction fighting continued immune an a MVA, also

of in patients to delve in at to be GeoVax. extended B-cell Development have now mounting an response this will to John? into who introduce response are But critical. the my transaction, For difficulty XXSX aplasia Head T-cell Business antibody pleasure likely vaccine post-therapy, it’s John order to Sharkey, deeper Dr. due to

John Sharkey

a designed undergone immunogenicity preventions strong you, for basis to safety provides evaluate segment positions enrolling market, in currently Thank vaccine with strongly approved XXSX mRNA transplant, recently was announced and vaccine currently X market multi-antigenic SARS-CoV-X of trial patients in Phase that the CAR-T propelling in us The relative cell the GeoVax’s Pfizer/BioNTech a to or the David. transaction to having unmet hematopoietic a a and need. presence significant medical therapy. It’s COHXXSX

In vaccinated a with grants potential to addition, response which We – to COVID-XX mRNA-based our immunogenic volunteers the well vaccine for the of believe larger segment. the previously market market. to underlying into X/X Phase accelerates use the a evaluate field the rights significantly the XXSX worldwide a as activities vaccines, of as transaction trial has COVID-XX us prevention development technology planned me healthy exclusive in we expand sMVA use other pardon as in announced significantly XXSX booster to the

Now, the this exciting Hope, to the Cell development lead City Diamond, I’d Hematology who and Dr. Department Hematopoietic discussion like product. Don? Don of of to pass Transplantation, Professor, of

Don Diamond

you. Thank

I achievement. finest delighted collaboration. be the My to has in since involved COHXXSX exciting developing consider am new been this of our vaccine we laboratory all, late First XXs, but

a data scientific some I properties favorable illustrates brought MVA. discuss along was breakthrough of the vaccine is virus, copy vial some synthetic Let’s the key of virtual of the on The slide that the the development vaccine. platform shown type the of

actual virus Wuhan FDA very were SARS-CoV-X we the clinical All found and into To pieces on main the infection. pivotal detailed components positive of We and models symptoms as at SARS-CoV-X in and COHXXSX, the DNA FPV non-human is MVA in components as We three once the to slide. and the humoral potent of nucleocapsid all clinical to volunteers hamsters pointed and split we another again, shown with this and evaluated slide. to that immunity characteristics summarized three despite was granted objectives the were we And the in In protection virologic as achieved that permission. the clever shown were genome investigate into against the conduct science, outcomes sophisticated filing, published be healthy aid elicited of virus, a the As the make on of from original the to investigations through form called genes preclinical illustrate and report the studies The strain trial. X and a that form had protective the recombine Phase recombined pieces. for that permission inserted slide. right developing the individual a trial virologic on to primates. triggered patent as goal to an from And helper of that published, detailed our arising We in cellular both one vaccine. plasmid was our vaccine right three into circular infection vaccine, applied immunity properties direction. viral various a the whole work in shown method, by into COHXXSX slide,

Here show response: strong immune main exciting the The a antibodies, These a illustrating for each illustrated levels, of that some there successful data all for neutralizing XXX durability X is full the days, and a protective dose all we beyond last bias components parameters. for out year. we THX to of show observations observation XXX the will antibodies, XXX generating solid days observed well bode vaccine response at subject T-cells the the is to that period days response here.

for This the with more are titers X level protective at durable important Here and we concern. show is neutralizing higher that the note, dose nasty tumor against antibody the and variants have Of responses magnitude variant. all synonymous beta dose of X immunity. level

data the of once and publicly All available study accepted. manuscript submit for this review peer the we will be is

eliciting are but panels we stabilize right Here days. Ellis associated out T-cells, are are vaccines rise that levels at results ones or and other T-cells that disease are even to for are don’t are XXX days, seeing Note from XXX are memory that spot of to after bad detects what levels are better chronic T-cells the They disappear. reasonable comparable apex, panels. and that immune What response. that good good durable fall days the at and any the never the the the T-cells XXX with left still enhancement, the

differentiate other recently Our CAR in to at treat who very the our will T-cell in by and hard severe cell recipients high think trial permitted COVID-XX. T-cell FDA our this from vaccines got risk sustaining stem patients of a still are response these products underway. We recently

platform may our We after booster the We begin rapid trial. immunity a to open and are expect durable shortly multiple long-lasting. accrual. vaccines that cause first different that is believe mRNA hope to excited trial more delivering We

would Chief Dr. I turn Scientific Officer. GeoVax over to to Mark? the Now, like Newman, discussion Mark

Mark Newman

vaccine to the you, this SARS-CoV-X there team but and also clinic, here. Obviously, vaccine of delighted and GeoVax the point our aspects Dr. XXSX to is have and in this with out to I to my vaccine Don. the only for the lead what candidate which as I Hope portfolio. Thank City clinical effort the forward partnership, to lead Diamond Not stage have work valuable other candidate move and now City going will the opportunity am are synergistic Hope multiple of are

MVA. Diamond David as City Hope is noted Dr. use and by of of on both vaccine Dodd, First, XXSX based the the

is the As comfortable you know from previous the foundational which presentations, GeoVax vector viral work with programs, variant. a is base with of and this excited of the new this to very modality

The nucleocapsid nucleocapsid and both multi-antigen vaccine specifically concept protein and spike bias. regardless our multi-antigen specific to the being induces the data and T-cell is before to of immune body antibodies proteins showed and both induces Diamond’s and is spike This expand as the in or immunogens. you. design as neutralizing SARS-CoV-XS design you to the variants, vaccine clear antibodies specifically SARS-CoV-X infections, the firm induce Second, the with responses and expressed circulating protein Again vaccine the T-cell response protein. in responses potency was the better implemented Dr. recall for the combat

we As responses the GeoVax specific approach the the responses, immune specifically induction on previously S-protein. also focused is immune beyond to presented, proteins of

As of T-cell clinical the next designed and vaccines, an generation ideal XXSX stage initial boost responses. City Hope as basis such, of augment represents the vaccine specifically to step

production a continuously schedule XXSX nicely increase avian consistency capacity ongoing with the GeoVax City the develop with the associated development line, very plans mesh efforts to and that a clinical clinical Hope and on Finally, manufacturing will based development of specifically growing cell process vaccine. is to

the think timely. significant GeoVax are I transaction and benefits this clearly program to of highly

I going Officer. to Now, am over Financial Chief the to Reynolds, Mark turn the presentation

Mark Reynolds

you, Thank Mark.

before, going just year. But think warrants. $X.X have but about increase stock our much was financials. December review, primarily with this to – the net know I increase, September original the Working this XX to compared call, were clearly our balance symbol, is under million and we are And talked development compared from balance us the am we million cash Those in this with pretty versus cash offering year-to-date the million under I due rapidly. $XX.X the the programs to I at proceeds $X.X XX of focus anyway, go of to conference on February offering also is was traded with traded our $X.X starting last $XX but GOVXW. of So this purpose received capital of of the million at have million. publicly exercise million $XX sheet balances through

statement, our the amount Grant portion generally million vaccine, expense XXXX ‘XX. ‘XX to large next the supporting fees expenses increase unlicense COVID-XX external the versus program, That with versus expenditures period of am of expenses relate legal Other process our Grant generally million $X.X associated and We periods increases year. and activity. of was while COVID-XX and our income fees, million. manufacturing capital a level in vaccine higher Gedeptin, to related on development the ‘XX U.S. timing of that program, patent premiums, continue which and revenues That license costs, revenues Grant capitalization. XXXX. Turning revenues insurance focus $X.X Collaboration’s increase during Army entirely on there fees, State tax, XXXX, activity is million from in related costs continuing. ‘XX versus to fever vaccine A will NIH personnel based consulting for in following from from X-month with figures minimal $X.X development, $X.X our the preparing level going were have our relates franchise supporting to in $XXX,XXX raises. the associated warrant the I comparative for a were Delaware with the Research period higher versus were expenses annual The through of to just our much includes that. $X.X Grant the Grant is amount the this and organization our of of G&A million XXXX. the loss in on were in XXXX the

$X.X debt $XXX,XXX on they $X.X And primarily there Those compared of for gain into company’s million the in W our net of in another the a of capital the expense with and full, outstanding. And extinguishment overall, share of amounts X.X ‘XX prior a September or traded of our few notes GeoVax X-month effect $X of in are in warrants year the structure, million if million are loan. per or for the exercisable And and period income million offerings can they the to of publicly share. of with $X.XX PPP XXXXof the year conference. this last variance $X.X common per million associated at other shares February bring X.X to due exercised a in loss $X.XX are outstanding, forgiveness on includes the Our share dilutive share year.

Our net cash flow from operating ‘XX million. nearly loss activities net was our of as during $X.X the same

also needs With fees of Hope the personnel support to are increase addition cash the the clinical of program clinical those the to only costs other program, programs. GDEPT direct and clinical for City the going obviously license in cost but programs, substantially, our and now September and for associated not the with in facilities, COVID-XX

aren’t and complete these that very that And overall I to our fundraising Q&A. to mid-XXXX. these programs existing any activities. specific going now to what forward-looking providing the for at can attractive reserves will the investment back is are research of rapidly during nature new strongly we estimates answer do be over David. a And cash programs to sufficient the I these am any While say questions time create opportunity this to turn through pipeline programs, believe product our we and we And happy call further costs move forward

David Dodd

Thank Mark. you,

immunooncology, we our our distribute the of capabilities a and clinical listed as that and to I’d financed November X to past Q&A on discussed areas and and some we rapidly focus achieving GeoVax. newly opening year. SARS-CoV-X changes enhancing highlight manufacture that products. key the resources within NASDAQ session, At have priority time, also recapitalized Before while status year about progress stage last a call quarterly like first It hosted our achieved the was we over year ago conference

manufacturing have program each have to And intended periods we support these to within slides immunooncology additional of the areas higher clinical now As of manufacturing the and these stage processes progressing and focused successfully. much underway address SARS-CoV-X. both illustrate, have of MVA and in and priorities pandemics. have remained the capabilities we Furthermore, we of even areas two we time program epidemics expansion on within capacity following

my colleagues to Now, had Dr. will leave I questions. and our Diamond Dr. but your Unfortunately, call, now answer has

you to period. the I to may prepared operator to the program. any questions for the turning address related is therefore XXSX question-and-answer on instructions am Newman have the call over vaccine

Operator

Jason question McCarthy go Thank you. [Operator Instructions] Group. Please from Today’s Maxim comes of ahead. first

Jason McCarthy

of Hi, guys. XXSX vaccines to for is bone vaccine data the mRNA marrow shows or immunocompromised? that patients questions. taking what We in with Xx, and is? have that Hope population you there get clearly, up seen Xx, the that well. solid like to pop there nothing. patients are have basis in transplant targeting publications the Is of like been some start I’d organ Xx Xx, Thanks out this are that transplant boosted people starting they the insufficient

Mark Newman

Yes.

Newman. Mark this So, is

that immunocompromised that answer the there ways. vaccines, Certainly anticipating Yes. that function S-only sub-optimally data mRNA me out existing right. patients. would two be I Let is And think that vaccines the there in

Now, City focusing transplant right. center. with for of this one Hope of population, on leading main world institution It’s this for the are a other reasons and dealing – therapy reasons cancer with one this the of is a they

Dr. patients with. period during patient Diamond that is this make of they for something type population. actually he that the these to how was And has motivated talked the data, So, reviewing of work

And here promise for definitely it’s – just the we initial the that reason is previously that’s real we with the yes, talked vaccine. like about GeoVax got some is focus. this So, think

both larger will and broad booster mention, these immunocompromised patients. world’s this and good own the population but are City a toxic what plus be T have that I are we of multi-antigen focusing adjuvanting, Hope lymphocytes than course, immunocompromised focused the is complex on. of initial little will helper that we of lymphocytes, inducing in think T on response, just better a functioning group much patients the chance where gives a And response, study will is we is one patient clearly antibodies, itself MVA leader, it its So, represent vector, more population

studies. So, opportunities to expand we anticipate

Jason McCarthy

X, like in that’s patient type terms vaccine what you are of you criteria to planned towards subject a in when quite in now mRNA as know you for right And rather long clear I subjects, it’s would that how look of different study doing think age? healthy the booster lab? Phase Great. even literature. the do There don’t if an enroll X, is opposed needs

you So, how you looking versus would in comp that specifically a an what for, or be work? study, be as would mRNA that booster doing XXSX the would

Mark Newman

Yes.

have work for And what the – what what there a manner. And to that So, the in to doable. this especially world, do, in really healthcare of is timely combination like you workers. actually the real would look is at is doable a you approach to is with

all volunteers immunize participate City will vaccine received For example, at these who workers. then in be to Pfizer the campaign of doctors and and nurses And literally Hope, of as healthcare the have healthy people part study. the

So, at at are we groups looking are healthcare to focus is anticipating immunocompromised. in recruiting But going on the be the or These any that – will be people be workers. the volunteers. would relatively not that looking healthy way are not healthy, limited we

Jason McCarthy

towards And or when that immunogenicity the of are? component data geared be what a responses T-cell large data

Mark Newman

thing, boosting Absolutely, that’s it’s our I pre-existing. mean But right.

antibodies, generated the domain, snapshot protein. that that including measuring S binding the you of RBD multiple is the to responses receptor vaccines COVID showed have they which neutralizing variants. a And the So, world to specific we of are understand data Diamond Dr. of

is and two looking to you later, what four it sample immunizing, so So, at weeks when their the prior came weeks response. on. later What boosting gave that are and happens in patient first happens what

responses responses. going is responses because done to differentiate induction, to to T-cell It’s the to obviously T-cell be where the important else. simply but control – taking of the not We we are we designed think us immune and are from is maintenance program. critically viral is difference. to everybody the it’s think efficacious So this where It’s

infection. dominant the is immunity response. – the T-cell more to highly for goal is So, protein the targets nucleoprotein, natural And in nucleocapsid of the immunity one broaden

target. So, a T-cell target nucleoprotein antibody the fit, and has perfect a it’s

Jason McCarthy

in And depth could trial readout have Great. neck, Phase jump over when of see a you program briefly you data Do to that from is timelines if that program? of we enrolling? just idea and in head the any X could X,

Mark Newman

answer somebody going that else that they am have I John, more for better David? to or got ask a –

David Dodd

– Right I Jason. size. this recently have expanded is the have now, that we will David, we just assumed just

So, five we thus in the Stanford, others the far just the go starting have forward. patients, but to are

be to So difficult at But in for more selection two final probably, meaningful are doing getting running conference to much the and basically readout. fully it sites process able this next the at right we time, IND, now, be to discuss call. address CRO the would would program. I of are and entire – transferring oversee that can the to up project a say a data the we new

Jason McCarthy

initiating And so? manufacturing,

David Dodd

Exactly.

Jason McCarthy

Got And since in that. it’s then second so it. in line the you had

second catapult varieties line And bar in to of for point. kind rates. GeoVax We relatively up take low activity a Is this other it’s the long-term considering that goal of some first possibly get that program? you checkpoints have with trade the seen different terms – Gedeptin you response have at got in we programs, what of is line and in that seen some a

David Dodd

that you at concept, right Yes, now it’s look just so being going on yes. if evaluated

Jason McCarthy

Got it.

fellows. Thank Okay. you,

David Dodd

you. Thank

Operator

Our comes Markets. with Brookline next from Capital ahead. Please Raja question Kumar go

Unidentified Analyst

on plan as immunodeficiency to patients, respect update. to it of or HIV you the With I XXSX calling Thanks diseases on like Kumar. well, to expand vaccine the immunocompromised do the am just cancer other development to patient [indiscernible] clinical immunocompromised groups limited for or for patients immunotherapy? in

Mark Newman

Yes.

to will process of are The to and expanding. of the act don’t bet of GeoVax discussion back is If of can the you focus going are be making from So data results, Kind evaluation. obviously, all will in those X that of want things in City we is management, diluted good depth and get seeing Hope, and interested get right? we driven, like discussing now under handoff out, all where be. the will we to but it of Phase some be first. We the

David Dodd

first got Kumar have certainly, This so I I this be immunocompromised initial I be what focused Dodd, group, us. But guided our in not me, learn my just are has will the you anticipation cohorts this excuse move Newman hope David are seeing trials, this appropriately represents But reason is that that are immunocompromised in for out, I simple what groups are that out able be multiple is will mean as data. into that vaccines we outlined, various to program the we say. pointed populations who additional but by of is that will the colleague, group, program will a and on the will current what high to initial we we by interest Kumar, say served there. being in well Mark other or

make broader, always felt void, immunocompromised filled are by that but we for what an of we opportunity, hoping much is MVA was a that very fill type targeted that area to it populations. And that And have could be so strong vaccines.

Unidentified Analyst

useful. That’s Got Right. it.

you for into the the days do in respect the looked T-cell to T-cell and hamsters. least the with you XX human the Now of as well? IgG immunoglobulin And responses, longevity comment trials? of them CMOX anti-spike also, of and if persistence it the moving you Have program, expect of beyond could persisted clinical what at the response results kind on

Mark Newman

next we Well, the will Well, is is yes, a the so models, to presentation. presentations testing model animal scientific. one and your week, ongoing. be first have animal scientific making And we question so about

be will data. our We introducing new

are we levels the protection single, the multiple only the in of in transgenic pathogenesis doses not mouse So, also evaluating model. hamster model, but protection

our at week, the time first So, those for released data will be next conference. next

MVA. presentations that associated that what program, indicates HIV others been We from end think as MVA our adjuvant process, through of VLP have the We And think as the have durable coming the the is nature or very you that durability, with effect and the data is from the are we the responses, a base series and of the between which getting far of which I year. is the scientific then FDA that’s CMOX induces response. a that now

very to looks expect Hope. something a of X year with would plan. months, I out the Dr. but he Diamond nice similar follow-up data So, City has shown mentioned, you has as very see But got X months, he to

be And look previously more seeing going said showed, there than you now durable Diamond mRNA. presenting the if are I at has with it. not as that is data that so and will every But durable that Dr. HIV our if responses are data the in generated we we I there the what as we program think indication to continually be

Unidentified Analyst

got it. Okay,

to So if I could And studies the going ongoing provide IND and to or some the enough wondering ongoing do color moving pre-clinical forward? just more you Sudan Marburg that for expect are viruses? NIH we the be studies with think the do application, was you tests finally, for

Mark Newman

So are we year, and hemorrhagic the presentations summary at one the World Diego vaccines presentation the again, San and making Vaccine be fever are. at the on end we a our in Conference where of of will

in induce rodent safety suggest driven in based these that and will primate non-human more are that good primates. made into testing and move be fully by will these process selection the driven don’t and probably predict these models Whether based they market the actually responses vaccines We not trial – be actually are those need. these clinical guinea a data that pigs are will are So, then – efficacy course, you trials, clinical on would or protective immunogenicity the indicate and you are we trial, are that just but of on anticipate in is would And that trials, primate. a forces.

of along to places that vaccines attention up moved be pushed in pointed have a then either funding clinical in boiling BARDA. or But sort So, our to processes Marburg are always of USAID, as more the outbreak couple Department testing. the as top – if and the of Marburg we’ve that a to the expands these out, always and along Defense pointed federal queue will world drive with as far we are flow likely

relationships. be will they they through so on is And we network tested rely what priority the determine their and actually

you push are of monkey the be actually looks We That going tell else’s the we can’t year down could, decision the data we ready to don’t. someone but I to that an at end have good. will us go that if to So, pathway. IND

Unidentified Analyst

questions. taking Okay, good. Great. Thanks for sounds my

Operator

to question-and-answer this conference over gentlemen, David for like back and I’d Ladies Dodd closing turn session. our to remarks. the concludes

David Dodd

you CMXX you progress. we next of and several over weeks as accelerate as milestones in clinical Gedeptin, of Okay, well resulting these upcoming capabilities other development for us in SARS-CoV-X. thank this for the start critical call this areas regarding for status forward thank We our just resources. Look updating months expansion participating and pace our immunooncology stage to of and two and and look XXSX, and as programs is our development sharing a within you achievements, everyone in milestone conference

thank continue I the Finally, and to want acknowledge parties us achieving assist that support, and success. Directors, and our staff GeoVax other of the to GeoVax Board many towards advise

part you. being and serving Have great safe pleasure For all shareholders a and us, it a our thank team. evening. of Again, this enjoyable of is

Operator

Thank concludes for today’s This today’s conference attending presentation. thank call. We you all you.

and have wonderful disconnect a You lines your evening. may now

GeoVax Labs (GOVX) 12 Nov 212021 Q3 Earnings call transcript